182 related articles for article (PubMed ID: 15302908)
1. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
Toner GC
J Clin Oncol; 2004 Oct; 22(19):3842-5. PubMed ID: 15302908
[No Abstract] [Full Text] [Related]
2. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
3. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
4. [Testis cancer markers. Clinical use].
Salesi N; Di Cocco B; Alghisi F; Calabretta F; Bossone G
Minerva Med; 2002 Oct; 93(5):365-9. PubMed ID: 12410169
[TBL] [Abstract][Full Text] [Related]
5. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Morris MJ; Bosl GJ
J Urol; 2000 Mar; 163(3):796-801. PubMed ID: 10687980
[TBL] [Abstract][Full Text] [Related]
6. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
7. Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Schatte EC; Lerner SP
J Urol; 2000 Nov; 164(5):1670. PubMed ID: 11203071
[No Abstract] [Full Text] [Related]
8. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
9. [Value of tumor marker positivity in germinal non-seminomatous tumors of the testis].
Bassetto MA; Franceschi T; Lenotti M; Pancheri F; Zaninelli M; Corgnati A; Cetto GL
J Nucl Med Allied Sci; 1990; 34(4 Suppl):89-90. PubMed ID: 1709212
[No Abstract] [Full Text] [Related]
10. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
11. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
12. Mediastinal germ cell tumors. A continuing odyssey.
Golbey RB
Chest Surg Clin N Am; 1994 Feb; 4(1):195-200. PubMed ID: 7519959
[TBL] [Abstract][Full Text] [Related]
13. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
[TBL] [Abstract][Full Text] [Related]
15. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of tumor markers in the treatment of germ cell tumors].
Germá Lluch JR; García del Muro X; Galán MC
Arch Esp Urol; 2000; 53(6):460-8. PubMed ID: 11002513
[TBL] [Abstract][Full Text] [Related]
17. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
Davis BE; Herr HW; Fair WR; Bosl GJ
J Urol; 1994 Jul; 152(1):111-3; discussion 114. PubMed ID: 7515445
[TBL] [Abstract][Full Text] [Related]
18. Testicular tumors.
Lightner DJ; Lange PH
Immunol Ser; 1990; 53():397-401. PubMed ID: 1713066
[No Abstract] [Full Text] [Related]
19. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
20. Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Mann K; Clemm C; Wilmanns W
Anticancer Res; 1997; 17(4B):3047-9. PubMed ID: 9329598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]